243 related articles for article (PubMed ID: 24396495)
1. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.
Marcus CS; Maxwell GL; Darcy KM; Hamilton CA; McGuire WP
J Cancer; 2014 Jan; 5(1):25-30. PubMed ID: 24396495
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer: the duplicity of CA125 measurement.
Karam AK; Karlan BY
Nat Rev Clin Oncol; 2010 Jun; 7(6):335-9. PubMed ID: 20368726
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients.
Fehm T; Heller F; Krämer S; Jäger W; Gebauer G
Anticancer Res; 2005; 25(3A):1551-4. PubMed ID: 16033059
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
Armstrong A; Otvos B; Singh S; Debernardo R
Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
[TBL] [Abstract][Full Text] [Related]
5. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
6. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.
Evangelista L; Palma MD; Gregianin M; Nardin M; Roma A; Nicoletto MO; Nardelli GB; Zagonel V
J Turk Ger Gynecol Assoc; 2015; 16(3):137-44. PubMed ID: 26401105
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
[TBL] [Abstract][Full Text] [Related]
9. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
10. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
[TBL] [Abstract][Full Text] [Related]
13. Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer.
Gadducci A; Sartori E; Zola P; Landoni F; Maggino T; Palai N; Fanucchi A; Katsaros D
Oncol Rep; 1996 Mar; 3(2):301-3. PubMed ID: 21594363
[TBL] [Abstract][Full Text] [Related]
14. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.
Gadducci A; Cosio S; Zola P; Landoni F; Maggino T; Sartori E
Int J Gynecol Cancer; 2007; 17(1):21-31. PubMed ID: 17291227
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
16. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
17. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
18. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
19. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
[TBL] [Abstract][Full Text] [Related]
20. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]